Clinical Trial Update: Does Caffeine Reduce Dipyridamole-Induced Protection Against Ischemia-Reperfusion Injury? [Phase 4]

View source ↗

Summary

This Phase 4 trial investigates whether caffeine alters the dipyridamole-induced protection against ischemia-reperfusion injury in cardiovascular disease, and t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease
• Ischemia-reperfusion Injury

Drugs mentioned

• Caffeine (caffeine)
• Dipyridamole (Dipyridamole)

Snippet

Sponsor: Radboud University Medical Center | Conditions: Cardiovascular Disease, Ischemia-Reperfusion Injury | Phase 4 | Status: COMPLETED